Registry for Germ Cell and Testicular Tumors

Germ Cell Tumor and Testicular Tumor DNA Registry

This study is trying to gather information from people with germ cell and testicular tumors, their families, and healthy individuals to better understand how these tumors develop and how to treat them.

Quick facts

• Study type: Observational
• Enrollment: 1000 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Memorial Sloan Kettering Cancer Center (other)
• Locations: 8 sites (Basking Ridge, New Jersey and 7 other locations)
• Trial ID: NCT02099734 on ClinicalTrials.gov

What this trial studies

This observational study aims to create a registry to enhance understanding of germ cell tumors and testicular tumors. It will include individuals diagnosed with these tumors, their relatives, and unrelated individuals without these tumors. By collecting data through questionnaires and biological samples, the study seeks to investigate the prevention, diagnosis, treatment, and outcomes associated with these tumors. The involvement of relatives and controls will help identify genetic and environmental factors influencing tumor development.

Who should consider this trial

Good fit: Ideal candidates include adults aged 18 and older with a diagnosis or suspicion of germ cell tumors or testicular masses.

Not a fit: Patients with a personal history of cancer (except non-melanoma skin cancer) or those without a family history of germ cell tumors may not benefit from this study.

Why it matters

Potential benefit: If successful, this registry could lead to improved prevention and treatment strategies for germ cell and testicular tumors.

How similar studies have performed: Other studies have successfully utilized registries to understand cancer genetics and outcomes, indicating potential for success in this approach.

Eligibility criteria

Inclusion Criteria:

Case Cohort

* Must be ≥ 18 years of age AND
* Must be an English-speaker AND
* Must have a diagnosis or suspicion of germ cell tumor and/or a testicular mass

Family Member Cohort

* Must be ≥ 18 years of age AND
* Must be an English-speaker AND
* Must be a blood relative of the proband. Family members of probands are eligible. These individuals need not have a diagnosis of GCT-TT, as they will be used for segregation analysis of suspected variants found in the proband.

Control Cohort

* Must be ≥ 18 years of age AND
* Must be an English-speaker AND
* Must not have a personal history of cancer, with the exception of non-melanoma skin cancer, AND
* Must not have a family history of germ cell tumor or testicular tumor AND
* Must not be a blood relative of controls enrolled in this study

Exclusion Criteria:

Where this trial is running

Basking Ridge, New Jersey and 7 other locations

• Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey, United States (RECRUITING)
• Memorial Sloan Kettering Monmouth — Middletown, New Jersey, United States (RECRUITING)
• Memorial Sloan Kettering Bergen — Montvale, New Jersey, United States (RECRUITING)
• Cold Springs Harbor Laboratory (Specimen Analysis) — Cold Spring Harbor, New York, United States (NOT_YET_RECRUITING)
• Memorial Sloan Kettering Commack — Commack, New York, United States (RECRUITING)
• Memorial Sloan Kettering Westchester — Harrison, New York, United States (RECRUITING)
• Memorial Sloan Kettering Cancer Center — New York, New York, United States (RECRUITING)
• Memorial Sloan Kettering Nassau — Uniondale, New York, United States (NOT_YET_RECRUITING)

Study contacts

• Principal investigator: Darren Feldman, MD — Memorial Sloan Kettering Cancer Center
• Study coordinator: Darren Feldman, MD

Conditions: Germ Cell Tumor, Testicular Tumor, 14-016